Reference
Heiland DH, et al. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine. Journal of Neuro-Oncology 126: 567-575, No. 3, Feb 2016. Available from: URL: http://doi.org/10.1007/s11060-015-2002-z - Germany
Rights and permissions
About this article
Cite this article
Bevacizumab. Reactions Weekly 1593, 40 (2016). https://doi.org/10.1007/s40278-016-15683-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-016-15683-3